<DOC>
	<DOCNO>NCT00002439</DOCNO>
	<brief_summary>The purpose study see ALRT1057 gel safe effective treat Kaposi 's sarcoma ( KS ) apply skin .</brief_summary>
	<brief_title>A Study ALRT 1057 Topical Gel Patients With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>This Phase 3 double-blind study . KS patient randomize 1 2 treatment arm . They receive either ALRT1057 gel placebo 12 week . If progressive disease KS note Week 12 , patient switch blinded treatment arm . If response disease progression persist least 4 week Week 12 occurs , treatment blind arm continue 4 additional week , response disease progression confirm . After time 12 week treatment , open-label ALRT1057 may receive .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<criteria>Information available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1997</verification_date>
</DOC>